2-methyl-4-(4-(trifluoromethoxy)phenyl)oxazole | 1531649-92-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-methyl-4-(4-(trifluoromethoxy)phenyl)oxazole
• 英文别名: 2-methyl-4-[4-(trifluoromethoxy)phenyl]-1,3-oxazole
• CAS: 1531649-92-9
• 化学式: C₁₁H₈F₃NO₂
• 分子量: 243.185
• InChiKey: NRSIKJOMZYLZQG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  35.3
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-methyl-4-(4-(trifluoromethoxy)phenyl)oxazole 在 N-氯代丁二酰亚胺 、 偶氮二异丁腈 、 溶剂黄146 作用下， 以 四氯化碳 为溶剂， 反应 5.0h， 生成
  参考文献：
  名称：

  Design, synthesis and structure–activity relationships of substituted oxazole–benzamide antibacterial inhibitors of FtsZ

  摘要：

  The design, synthesis and structure-activity relationships of a series of oxazole-benzamide inhibitors of the essential bacterial cell division protein FtsZ are described. Compounds had potent anti-staphylococcal activity and inhibited the cytokinesis of the clinically-significant bacterial pathogen Staphylococcus aureus. Selected analogues possessing a 5-halo oxazole also inhibited a strain of S. aureus harbouring the glycine-to-alanine amino acid substitution at residue 196 of FtsZ which conferred resistance to previously reported inhibitors in the series. Substitutions to the pseudo-benzylic carbon of the scaffold improved the pharmacokinetic properties by increasing metabolic stability and provided a mechanism for creating pro-drugs. Combining multiple substitutions based on the findings reported in this study has provided small-molecule inhibitors of FtsZ with enhanced in vitro and in vivo antibacterial efficacy. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.11.002
• 作为产物：
  描述：

  乙酰胺 、 2-溴-1-4-(三氟甲氧基)苯基乙酮 反应 12.0h， 以70%的产率得到2-methyl-4-(4-(trifluoromethoxy)phenyl)oxazole
  参考文献：
  名称：

  ANTIMICROBIAL AGENTS

  摘要：

  该发明提供了式(I)的化合物： 其中R1-R3，n和W具有规范中定义的任何值，并且其盐。这些化合物具有良好的溶解性，可用于治疗细菌感染。

  公开号：

  US20150133465A1

文献信息

• 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis
  申请人：Tsubouchi Hidetsugu

  公开号：US20080119478A1

  公开（公告）日：2008-05-22

  The present invention provides a 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound represented by the following general formula: (1) in the above formula (1), R1 represents a hydrogen atom or C1-C6 alkyl group, n represents an integer of 0 to 6, R1 and —(CH2) n R2 may form a spiro ring represented by the formula (30) below, together with the adjacent carbon atom (in the formula below, RRR represents a piperidyl group which may have substituents on the piperidine ring), (30) and R2 represents a benzothiazolyloxy group, quinolyloxy group, pyridyloxy group or the like. The present compound has an excellent bactericidal action against Mycobacterium tuberculosis , multi-drug-resistant Mycobacterium tuberculosis , and atypical acid-fast bacteria.

  本发明提供了一种由下述通式（1）表示的2,3-二氢-6-硝基咪唑[2,1-b]噁唑化合物： 在上述式（1）中，R1代表氢原子或C1-C6烷基，n代表0到6的整数，R1和—(CH2)nR2可以与相邻的碳原子形成如下式（30）所示的螺环，其中，在下式中，RRR代表可能在哌啶环上具有取代基的哌啶基： （30）且R2代表苯并噻唑氧基、喹啉氧基、吡啶氧基或类似基团。该化合物对结核分枝杆菌、多重耐药结核分枝杆菌和非典型酸杆菌具有优异的杀菌作用。
• Antimicrobial agents
  申请人：Rutgers, The State University of New Jersey

  公开号：US10071082B2

  公开（公告）日：2018-09-11

  The invention provides compounds of formula (I): wherein R1-R3, n, and W have any of the values defined in the specification, and salts thereof. The compounds have good solubility and are useful for treating bacterial infections.

  本发明提供了式 (I) 的化合物： 其中 R1-R3、n 和 W 具有说明书中定义的任一数值，以及它们的盐类。这些化合物具有良好的溶解性，可用于治疗细菌感染。
• 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP1678185B1

  公开（公告）日：2008-10-08
• US8163753B2
  申请人：——

  公开号：US8163753B2

  公开（公告）日：2012-04-24
• US9458150B2
  申请人：——

  公开号：US9458150B2

  公开（公告）日：2016-10-04